Cidara Therapeutics, Inc. announced that the FDA has accepted the company’s Investigational New Drug application for its lead flu drug-Fc conjugate, CD388 – a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza.
[Cidara Therapeutics, Inc.]
Sorry, but the selected Zotpress account can't be found.